Opipramol

Overview

Opipramol, sold under the brand name Insidon among others, is an anxiolytic and tricyclic antidepressant that is used throughout Europe. Despite chemically being a tricyclic dibenzazepine (iminostilbene) derivative similar to imipramine, opipramol is not a monoamine reuptake inhibitor like most other tricyclic antidepressants, and instead acts primarily as a sigma-1 receptor agonist. It was developed by Schindler and Blattner in 1961.[1–6] WP

Uses, dosage and effects

Medical uses

Opipramol is typically used in the treatment of generalized anxiety disorder (GAD) and somatoform disorders. Preliminary studies suggest that opipramol shows potential clinical significance in the treatment of severe sleep bruxism.[4][7][8] WP

Risks and side effects

Contraindications

Contraindications of opipramol include: WP⚠ Wikipedia itself has flagged this text: citation needed.

• In patients with hypersensitivity to opipramol or another component of the formulation WP
• Acute alcohol, sedative, analgesic, and antidepressant intoxications WP
• Acute urinary retention WP
• Acute delirium WP
• Untreated narrow-angle glaucoma WP
• Benign prostatic hyperplasia with residual urinary retention WP
• Paralytic ileus WP
• Pre-existing higher-grade atrioventricular blockages or diffuse supraventricular or ventricular stimulus conduction disturbances WP
• Combination with monoamine oxidase inhibitor (MAOI) WP

Pregnancy and lactation

Experimental animal studies did not indicate injurious effects of opipramol on the embryonic development or fertility. Opipramol should only be prescribed during pregnancy, particularly in the first trimester, for compelling indication. It should not be used during lactation and breastfeeding, since it passes into breast milk in small quantities. WP⚠ Wikipedia itself has flagged this text: citation needed.

Side effects

Frequently (≥1% to <10%) reported adverse reactions with opipramol, especially at the beginning of the treatment, include fatigue, dry mouth, blocked nose, hypotension, and orthostatic dysregulation. WP

Adverse reactions reported occasionally (≥0.1% to <1%) include dizziness, stupor, micturition disturbances, vigilance, accommodation disturbances, tremor, weight gain, thirst, allergic skin reactions (rash, urticaria), abnormal ejaculation, erectile impotence, constipation, transient increases in liver enzymes, tachycardia, and palpitations.[7][9–12] WP

Rarely (≥0.01% to <0.1%) reported adverse reactions include excitation, headache, paresthesia especially in elderly patients, restlessness, sweating, sleep disturbances, edema, galactorrhea, urine blockage, nausea and vomiting, fever, collapse conditions, stimulation conducting disturbances, intensification of present heart insufficiency, blood profile changes particularly leukopenia, confusion, delirium, stomach complaints, taste disturbance, and paralytic ileus especially with sudden discontinuation of a longer-term high-dose therapy.[7][13] WP

Very rarely (<0.01%) reported adverse reactions include seizures, motor disorders (akathisia, dyskinesia, ataxia), polyneuropathy, glaucoma, anxiety, hair loss, agranulocytosis, severe liver dysfunction after long-term treatment, jaundice, and chronic liver damage.[7][12][14] WP

Overdose

Symptoms of intoxication from overdose include drowsiness, insomnia, stupor, agitation, coma, transient confusion, increased anxiety, ataxia, convulsions, oliguria, anuria, tachycardia or bradycardia, arrhythmia, AV block, hypotension, shock, respiratory depression, and, rarely, cardiac arrest. WP⚠ Wikipedia itself has flagged this text: citation needed.

Interactions

Interactions

While opipramol is not a monoamine reuptake inhibitor, any irreversible MAOIs should still be discontinued at least 14 days before treatment [Why?]. Opipramol can compete with other tricyclic antidepressants, beta blockers, antiarrhythmics (of class 1c), and other drugs for microsomal enzymes, which can lead to slower metabolism and higher plasma concentrations of these drugs. Co-administration of antipsychotics (e.g., haloperidol, risperidone) can increase the plasma concentration of opipramol. Barbiturates and anticonvulsants can reduce the plasma concentration of opipramol and thereby weaken its therapeutic effect.[7] WP

Pharmacology

Pharmacodynamics

Opipramol acts as a high affinity sigma receptor agonist, primarily of the σ₁ subtype, but also of the σ₂ subtype with lower affinity. In one study of σ₁ receptor ligands that also included haloperidol, pentazocine, (+)-3-PPP, ditolylguanidine, dextromethorphan, SKF-10,047 ((±)-alazocine), ifenprodil, progesterone, and others, opipramol showed the highest affinity (Kᵢ = 0.2–0.3) for the guinea pig σ₁ receptor of all the tested ligands except haloperidol, which it was approximately equipotent with. The sigma receptor agonism of opipramol is thought to be responsible for its therapeutic benefits against anxiety and depression.[4][5][7][15] WP

Unlike other TCAs, opipramol does not inhibit the reuptake of serotonin or norepinephrine. However, it does act as a high affinity antagonist of the histamine H₁ receptor and is a low to moderate affinity antagonist of the dopamine D₂, serotonin 5-HT₂, and α₁-adrenergic receptors. H₁ receptor antagonism accounts for its antihistamine effects and associated sedative side effects. In contrast to other TCAs, opipramol has very low affinity for the muscarinic acetylcholine receptors and virtually no anticholinergic effects.[4][7][16][17][18] WP

Sigma receptors are a set of proteins located in the endoplasmic reticulum. σ₁ receptors play key role in potentiating intracellular calcium mobilization thereby acting as sensor or modulator of calcium signaling. Occupancy of σ₁ receptors by agonists causes translocation of the receptor from endoplasmic reticulum to peripheral areas (membranes) where the σ₁ receptors cause neurotransmitter release. Opipramol is said to have a biphasic action, with prompt initial improvement of tension, anxiety, and insomnia followed by improved mood later. Hence, it is an anxiolytic with an antidepressant component. After sub-chronic treatment with opipramol, σ₂ receptors are significantly downregulated but σ₁ receptors are not.[7] WP

Pharmacokinetics

Opipramol is rapidly and completely absorbed by the gastrointestinal tract. The bioavailability of opipramol amounts to 94%. After single oral administration of 50 mg, the peak plasma concentration of the drug is reached after 3.3 hours and amounts to 15.6 ng/mL. After single oral administration of 100 mg the maximum plasma concentration is reached after 3 hours and amounts to 33.2 ng/mL. Therapeutic concentrations of opipramol range from 140 to 550 nmol/L. The plasma protein binding amounts to approximately 91% and the volume of distribution is approximately 10 L/kg. Opipramol is partially metabolized in the liver to deshydroxyethylopipramol. Metabolism occurs through the CYP2D6 isoenzyme. Its terminal half-life in plasma is 6–11 hours. About 70% is eliminated in urine with 10% unaltered. The remaining portion is eliminated through feces.[7][19] WP

History

History

Opipramol was developed by Geigy. It first appeared in the literature in 1952 and was patented in 1961. The drug was first introduced for use in medicine in 1961. Opipramol was one of the first TCAs to be introduced, with imipramine marketed in the 1950s and amitriptyline marketed in 1961.[20] WP

Legal status

Generic names

Opipramol is the English, German, French, and Spanish generic name of the drug and its INN (International Nonproprietary Name), BAN (British Approved Name), and DCF (Dénomination Commune Française), while opipramol hydrochloride is its USAN (United States Adopted Name), BANM (British Approved Name), and JAN (Japanese Accepted Name). Its generic name in Italian and its DCIT (Denominazione Comune Italiana) is opipramolo and in Latin is opipramolum.[1][2][3][21] WP

Brand names

Opipramol is marketed under the brand names Deprenil, Dinsidon, Ensidon, Insidon, Insomin, Inzeton, Nisidana, Opipram, Opramol, Oprimol, Pramolan, and Sympramol among others.[1][2][3] WP

Chemistry

Formula

C23H29N3O PC

CAS number

315-72-0 PC

Molar mass (g/mol)

363.5 PC

IUPAC name (computed by PubChem)

2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol PC

SMILES

C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO PC

InChIKey

YNZFUWZUGRBMHL-UHFFFAOYSA-N PC

PubChem CID

9417

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014
2. Other Index Nominum 2000: International Drug Directory. 2000
3. Other Opipramol
4. Journal / agency Möller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. Journal of Clinical Psychopharmacology. February 2001. doi:10.1097/00004714-200102000-00011 · PMID 11199949
5. Journal / agency Müller WE, Siebert B, Holoubek G, Gentsch C. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry. November 2004. doi:10.1055/s-2004-832677 · PMID 15547785
6. Journal / agency Grosser HH, Ryan E. Drug Treatment of Anxiety: A Controlled Study of Opipramol and Chlordiazepoxide. The British Journal of Psychiatry. February 1965. doi:10.1192/bjp.111.471.134 · PMID 14270525
7. Journal / agency Mohapatra S, Rath NM, Agrawal A, Verma J. Opipramol: A Novel Drug. Delhi Psychiatry Journal. October 2013
8. Journal / agency Wieckiewicz M, Martynowicz H, Wieczorek T, Wojakowska A, Sluzalec-Wieckiewicz K, Gac P, Poreba R, Mazur G, Winocur E, Smardz J. Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management-Preliminary Study on New Therapeutic Path. Brain Sciences. January 2021. doi:10.3390/brainsci11020146 · PMID 33499332 · PMC7911172
9. Journal / agency Carpéné C, Les F, Mercader J, Gomez-Zorita S, Grolleau JL, Boulet N, Fontaine J, Iglesias-Osma MC, Garcia-Barrado MJ. Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. Pharmaceuticals. March 2020. doi:10.3390/ph13030041 · PMID 32151075 · PMC7151722
10. Journal / agency Jepson K, Beaumont G. A Comparative Trial of Opipramol and Chlordiazepoxide in the Treatment of Anxiety. Journal of International Medical Research. March 1973. doi:10.1177/030006057300100301
11. Journal / agency Volz HP, Möller HJ, Reimann I, Stoll KD. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. European Neuropsychopharmacology. May 2000. doi:10.1016/S0924-977X(00)00074-2 · PMID 10793324
12. Journal / agency Gahr M, Hiemke C, Connemann BJ. Update Opipramol. Fortschritte der Neurologie-Psychiatrie. March 2017. doi:10.1055/s-0043-100762 · PMID 28320023
13. Journal / agency Krysta K, Murawiec S, Warchala A, Zawada K, Cubała WJ, Wiglusz MS, Jakuszkowiak-Wojten K, Krzystanek M, Krupka-Matuszczyk I. Modern indications for the use of opipramol. Psychiatria Danubina. September 2015. PMID 26417811
14. Journal / agency Braun JS, Geiger R, Wehner H, Schäffer S, Berger M. Hepatitis caused by antidepressive therapy with maprotiline and opipramol. Pharmacopsychiatry. July 1998. doi:10.1055/s-2007-979319 · PMID 9754852
15. Journal / agency Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proceedings of the National Academy of Sciences of the United States of America. July 1996. doi:10.1073/pnas.93.15.8072 · PMID 8755605 · PMC38877
16. Journal / agency Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R. Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics. Naunyn-Schmiedeberg's Archives of Pharmacology. February 2012. doi:10.1007/s00210-011-0704-0 · PMID 22033803
17. Journal / agency Holoubek G, Müller WE. Specific modulation of sigma binding sites by the anxiolytic drug opipramol. Journal of Neural Transmission. October 2003. doi:10.1007/s00702-003-0019-5 · PMID 14523629
18. Other Botana LM, Loza M. Therapeutic Targets: Modulation, Inhibition, and Activation. 20 April 2012
19. Journal / agency Gutteck U, Rentsch KM. Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clinical Chemistry and Laboratory Medicine. December 2003. doi:10.1515/CCLM.2003.240 · PMID 14708881
20. Journal / agency Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chemical Communications. July 2009. doi:10.1039/b903035m · PMID 19557250
21. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.